Dylan J Martini1, Meredith R Kline1, Yuan Liu2, Julie M Shabto1, Bradley C Carthon1, Greta Anne Russler3, Lauren Yantorni3, Emilie Elise Hitron3, Sarah Caulfield4, Jamie M Goldman1, Wayne B Harris1, Omer Kucuk1, Viraj A Master5, Mehmet Asim Bilen6. 1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute of Emory University, Atlanta, GA, USA. 2. Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA. 3. Winship Cancer Institute of Emory University, Atlanta, GA, USA. 4. Winship Cancer Institute of Emory University, Atlanta, GA, USA; Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA. 5. Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. 6. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute of Emory University, Atlanta, GA, USA. Electronic address: mehmet.a.bilen@emory.edu.
Abstract
BACKGROUND: Cabozantinib is an effective treatment for metastatic renal cell carcinoma (mRCC). The international mRCC database consortium (IMDC) criteria is the gold standard for risk stratification in mRCC. We created a risk scoring system specific for mRCC patients treated with cabozantinib. METHODS: We conducted a retrospective review of 87 patients with mRCC treated with cabozantinib at Winship Cancer Institute from 2015 to 2019. Overall survival (OS) and progression free survival (PFS) were used to measure clinical outcomes. Upon variable selection in multivariable analysis (MVA), elevated baseline monocyte-to-lymphocyte ratio (MLR), sarcomatoid histologic component, ECOG PS > 1, and absence of bone metastases were each assigned 1 point. A three-group risk scoring system was then created: low (score=0-1), intermediate (score=2), and high risk (score=3-4). The Cox proportional hazard model and Kaplan-Meier method were used for survival analyses. RESULTS: The median age was 62 years-old and the majority were males (71%) with clear-cell RCC (75%). Most (67%) received at least 1 prior line of systemic therapy. High risk and intermediate risk pts had significantly shorter OS (high risk HR: 13.84, p<0.001; intermediate risk HR: 3.50, p = 0.004) and PFS (high risk HR: 7.31, p<0.001; intermediate risk HR: 1.87, p = 0.053) compared to low risk patients in MVA. CONCLUSIONS: RCC patients treated with cabozantinib may benefit from specific risk stratification criteria using RCC histology, ECOG PS, sites of metastatic disease, and MLR. These variables are easily accessible in the clinical setting and may be helpful to determine which mRCC patients may benefit from treatment with cabozantinib.
BACKGROUND: Cabozantinib is an effective treatment for metastatic renal cell carcinoma (mRCC). The international mRCC database consortium (IMDC) criteria is the gold standard for risk stratification in mRCC. We created a risk scoring system specific for mRCC patients treated with cabozantinib. METHODS: We conducted a retrospective review of 87 patients with mRCC treated with cabozantinib at Winship Cancer Institute from 2015 to 2019. Overall survival (OS) and progression free survival (PFS) were used to measure clinical outcomes. Upon variable selection in multivariable analysis (MVA), elevated baseline monocyte-to-lymphocyte ratio (MLR), sarcomatoid histologic component, ECOG PS > 1, and absence of bone metastases were each assigned 1 point. A three-group risk scoring system was then created: low (score=0-1), intermediate (score=2), and high risk (score=3-4). The Cox proportional hazard model and Kaplan-Meier method were used for survival analyses. RESULTS: The median age was 62 years-old and the majority were males (71%) with clear-cell RCC (75%). Most (67%) received at least 1 prior line of systemic therapy. High risk and intermediate risk pts had significantly shorter OS (high risk HR: 13.84, p<0.001; intermediate risk HR: 3.50, p = 0.004) and PFS (high risk HR: 7.31, p<0.001; intermediate risk HR: 1.87, p = 0.053) compared to low risk patients in MVA. CONCLUSIONS: RCC patients treated with cabozantinib may benefit from specific risk stratification criteria using RCC histology, ECOG PS, sites of metastatic disease, and MLR. These variables are easily accessible in the clinical setting and may be helpful to determine which mRCC patients may benefit from treatment with cabozantinib.
Authors: Ruben Raychaudhuri; Matthew J Riese; Kathryn Bylow; John Burfeind; Alexander C Mackinnon; Parag P Tolat; Kenneth A Iczkowski; Deepak Kilari Journal: Clin Genitourin Cancer Date: 2017-05-25 Impact factor: 2.872
Authors: Ross D Dolan; Louise Daly; Wei M J Sim; Marie Fallon; Aoife Ryan; Donald C McMillan; Barry J Laird Journal: Clin Nutr Date: 2019-12-27 Impact factor: 7.324
Authors: Mehmet A Bilen; Dylan J Martini; Yuan Liu; Colleen Lewis; Hannah H Collins; Julie M Shabto; Mehmet Akce; Haydn T Kissick; Bradley C Carthon; Walid L Shaib; Olatunji B Alese; Rathi N Pillai; Conor E Steuer; Christina S Wu; David H Lawson; Ragini R Kudchadkar; Bassel F El-Rayes; Viraj A Master; Suresh S Ramalingam; Taofeek K Owonikoko; R Donald Harvey Journal: Cancer Date: 2018-10-17 Impact factor: 6.860
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: Claribel Simmons; Donald C McMillan; Sharon Tuck; Cat Graham; Alistair McKeown; Mike Bennett; Claire O'Neill; Andrew Wilcock; Caroline Usborne; Kenneth C Fearon; Marie Fallon; Barry J Laird Journal: Oncologist Date: 2019-04-11
Authors: Marie-Therese Haider; Keith D Hunter; Simon P Robinson; Timothy J Graham; Eva Corey; T Neil Dear; Russell Hughes; Nicola J Brown; Ingunn Holen Journal: Bone Date: 2015-08-14 Impact factor: 4.398
Authors: Aly-Khan A Lalani; Wanling Xie; Dylan J Martini; John A Steinharter; Craig K Norton; Katherine M Krajewski; Audrey Duquette; Dominick Bossé; Joaquim Bellmunt; Eliezer M Van Allen; Bradley A McGregor; Chad J Creighton; Lauren C Harshman; Toni K Choueiri Journal: J Immunother Cancer Date: 2018-01-22 Impact factor: 13.751